Scholar Rock Wins FDA Approval for Isembyld, First Drug to Target SMA Muscle Loss
Source Summary
Scholar Rock has received FDA approval for Isembyld, a drug designed to address muscle loss in spinal muscular atrophy (SMA). In late-stage clinical trials, Isembyld improved motor skills in young patients over one year when used alongside an SMN2-targeting drug.
Why it matters
This approval marks the first FDA-authorized treatment specifically targeting muscle loss in SMA, expanding therapeutic options for patients with this rare genetic disorder.
